Inhibitory Effect of Ginsenoside Rg3 Combined With 5-Fluorouracil on Tumor Angiogenesis and Tumor Growth of Colon Cancer in Mice: An Experimental Study

To evaluate the inhibitory effect of ginsenoside Rg3 combined with 5-fluorouracil (5-FU) on tumor angiogenesis and tumor growth in colon cancer in mice.Methods CT26 mouse model of colon cancer was established and the mice were randomly assigned to the control group, the ginsenoside Rg3 group, the 5-FU group, and the Rg3 combined with 5-FU group. The 5-FU group was injected intraperitoneally at the dose of 20 mg/kg, 0.2 mL/animal, and once a day for 10 days. Treatment for the Rg3 group was given at the dose of 20 mg/kg, 0.2 mL/animal, and once a day for 21 days via gastric gavage. The dose and the mode of treatment for the Rg3+5-FU combination group were the same as those for the 5-FU and the Rg3 group. The control group was intraperitoneally injected with 0.2 mL/d of normal saline for 10 days. The expression of vascular endothelial growth factor (VEGF) and CD31 and the microvascular density (MVD) of the tumor tissues were examined by immunohistochemistry. The blood flow signals and tumor necrosis were examined by color Doppler flow imaging (CDFI). The quality of life, survival rate, tumor volume, tumor mass, and tumor inhibition rate of the mice were monitored.Results After 21 days of treatment, the tumor volume and the tumor mass of all treatment groups were significantly decreased compared with those the control group, with the combination treatment group exhibiting the most significant decrease. The tumor inhibition rates of the Rg3 group, the 5-FU group, and the combination group were 29.96%, 68.78%, and 73.42%, respectively. Rg3 treatment alone had inhibitory effect on tumor growth to a certain degree, while 5-FU treatment alone or 5-FU combined with Rg3 had a stronger inhibitory effect on tumor growth. The tumor inhibition rate of the combination group was higher than that of the 5-FU group, but the difference was not statistically significant (P>0.05). Color Doppler ultrasound showed that there were multiple localized and large tumor necrotic areas that were obvious and observable in the Rg3 group and the combination group, and that there were only small tumor necrotic areas in the 5-FU group and the control group. The tumor necrosis rate of the combination group was (55.63±3.12)%, which was significantly higher than those of the other groups (P<0.05). CDFI examination of the blood flow inside of the tumor of the mice showed that the blood flow signals in the combination group were mostly grade 0-Ⅰ, and that the blood flow signals in the control group were the most abundant, being mostly grade Ⅱ-Ⅲ. The abundance of the blood flow signals in the Rg3 and 5-FU groups were between those of the control group and the combination group. Compared with those of the control group, the expression levels of MVD and VEGF in the tumor tissues of the Rg3 group, the 5-FU group, and the combination group were significantly decreased, with the combination group showing the most significant decrease (P<0.05). HE staining results indicated that there was significant tumor necrosis in mice in the control group and that there were more blood vessels. In contrast, in the tumor of the Rg3 group and the 5-FU group, there were fewer blood vessels and necrotic gaps appeared within the tumors. In the combination group, the tumor tissues had the fewest blood vessels and rope-like necrosis was observed. The mice started dying on the 18th day after treatment started, and all the mice in the control group died on the 42nd day. By this time, there were 3, 5, and 7 mice still alive in the Rg3 group, the 5-FU group, and the combination group, respectively, presenting a survival rate of 30%, 50%, and 70%, respectively. All mice in all the groups died on day 60 after treatment started.Conclusion Ginsenoside Rg3 combined with 5-FU can significantly inhibit tumor angiogenesis and tumor growth of colon cancer in mice and improve the survival and quality of life of tumor-bearing mice.


Keywords: Ginsenoside Rg3,  5-fluorouracil,  Colon cancer,  Tumor growth,  Tumor angiogenesis

SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin，2021，71(3): 209–249. doi: 10. 3322/caac.21660.

XU M Y， SHAN T H， ZENG H M. Global incidence and mortality of colon cancer and rectal cancer in 2020. Jiangsu J Prev Med，2023，34(1): 12–16. doi: 10.13668/j.issn.1006-9070.2023.01.003.

KAMRAN S， SINNIAH A， CHIK Z， et al. Diosmetin exerts synergistic effects in combination with 5-fluorouracil in colorectal cancer cells. Biomedicines，2022，10(3): 531. doi: 10.3390/biomedicines10030531.

SHOARI A， KHODABAKHSH F， AHANGARI COHAN R， et al. Anti-angiogenic peptides application in cancer therapy; a review. Res Pharm Sci，2021，16(6): 559–574. doi: 10.4103/1735-5362.327503.

LIU M R， ZHAO H Y. Progress in the application of antiangiogenic drugs in the treatment of colorectal cancer. Oncol Progress，2022，20(7): 664–667.

HU S， ZHU Y， XIA X， et al. Ginsenoside Rg3 prolongs survival of the orthotopic hepatocellular carcinoma model by inducing apoptosis and inhibiting angiogenesis. Anal Cell Pathol (Amst)，2019，2019: 3815786. doi: 10.1155/2019/3815786.

CHEN D， NI J S， WANG X R， et al. MCF-7 cell apoptosis induced by 20 (S)-ginsendoside Rg3 in mammary carcinoma. J Jilin Univ (Med Edi)， 2008(212): 610–614. doi: 10.13481/j.1671-587x.2008.04.048.

WEIDNER N， SEMPLE J P， WELCH W R. et al. Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. New Engl J Med，1991，324: 1. doi: 10.1056/NEJM199101033240101.

ADLER D D， CARSON P L， RUBIN J M， et al. Doppler ultrasound color flow imaging in the study of breast cancer; Preliminary findings. Ultrasound Med Biol，1990，16(6): 553–559. doi: 10.1016/0301-5629(90) 90020-D.

CRUZ-ORIVE L M. Precision of Cavalieri sections and slices with local errors. J Microsc，1999，193: 182–98. doi: 10.1046/j.1365-2818.1999.00460.x.

ULLAH H M A， SABA E， LEE Y Y， et al. Restorative effects of Rg3-enriched Korean Red Ginseng and Persicaria tinctoria extract on oxazolone-induced ulcerative colitis in mice. J Ginseng Res，2022，46(5): 628–635. doi: 10.1016/j.jgr.2021.07.001.

SUN D， ZOU Y， SONG L， et al. A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer. Acta Pharm Sin B，2022，12(1): 378–393. doi: 10.1016/j.apsb.2021.06.005.

LV S， CHEN X， CHEN Y， et al. Ginsenoside Rg3 induces apoptosis and inhibits proliferation by down-regulating TIGAR in rats with gastric precancerous lesions. BMC Complement Med Ther，2022，22(1): 188. doi: 10.1186/s12906-022-03669-z.

JIANG J W， CHEN X M， CHEN X H， et al. Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway. World J Gastroenterol，2011，17(31): 3605–3613. doi: 10.3748/wjg.v17.i31.3605.

HONG H， MILDRED Y， KEVIN H L， et al. Involvement of G proteins of the Rho family in the regulation of Bcl-2-like protein expression and caspase 3 activation by gastrins. Cell Signal，2008，20(1): 83–93. doi: 10. 1016/j.cellsig.2007.08.018.

XIA J， ZHANG S， ZHANG R， et al. Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes. J Nanobiotechnology，2022，20(1): 414. doi: 10.1186/s12951-022-01623-2.

LI M， WANG X， WANG Y， et al. Strategies for remodeling the tumor microenvironment using active ingredients of Ginseng-A promising approach for cancer therapy. Front Pharmacol，2021，12: 797634. doi: 10. 3389/fphar.2021.797634.

PENG X， DING C， ZHAO Y， et al. Poloxamer 407 and hyaluronic acid thermosensitive hydrogel-encapsulated Ginsenoside Rg3 to promote skin wound healing. Front Bioeng Biotechnol，2022，10: 831007. doi: 10.3389/fbioe.2022.831007.

WANG J， ZENG L， ZHANG Y， et al. Pharmacological properties, molecular mechanisms and therapeutic potential of ginsenoside Rg3 as an antioxidant and anti-inflammatory agent. Front Pharmacol，2022，13: 975784. doi: 10.3389/fphar.2022.975784.

JIANG C， MIAO Y Q， ZHOU W L， et al. Research progress of ginsenoside Rg3 in anticancer activities. Chin Clin Oncol，2017，22(7): 664–667. doi: 10.3969/j.issn.1009-0460.2017.07.019.

DING W B， NING Q， XIA Z， et al. Study on synergistic anti-tumor effect of Shuangdan Capsules combined with 5-FU on hepatocellular carcinoma cells Huh-7 and xenograft mice. China J Chin Mat Med，2020， 45(23): 5762–5769. doi: 10.19540/j.cnki.cjcmm.20201102.401.